Skip to content
Anticancer Bioscience
  • Home
  • About Us
    • Our Heritage
    • Operations
    • Team
    • Investors
  • Science
    • Discovery Platforms
    • Pipeline
    • Publications
  • Partners
    • Academic Partners
    • Commercial Partners
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Careers
  • Contact Us
Anticancer Bioscience

Press Releases

September 22, 2022

Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip

Read More
May 18, 2022

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology

Read More
April 19, 2022

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader

Read More
January 17, 2022

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics

Read More
January 8, 2022

Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s Almanac

Read More
December 20, 2021

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China

Read More
October 25, 2021

Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon Review

Read More
October 14, 2021

Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer Therapy

Read More
September 9, 2021

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments

Read More
July 14, 2021

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

Read More
May 11, 2021

Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer

Read More
February 8, 2021

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

Read More
January 12, 2021

Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time

Read More
  • Chengdu, China
  • St Andrews, UK
  • San Francisco, USA
  • Sydney, Australia
  • Hyderabad, India
  • Linkedin
  • Twitter
  • Anticancer Bioscience © 2021
  • info@anticancerbio.com

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

  • Home
  • About Us
    • Our Heritage
    • Operations
    • Team
    • Investors
  • Science
    • Discovery Platforms
    • Pipeline
    • Publications
  • Partners
    • Academic Partners
    • Commercial Partners
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Careers
  • Contact Us